Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
207940 · KRX · South Korea · Health care
In shortSamsung Biologics is profitable, generates cash and carries moderate debt, with revenue growing (+30.3% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 45.4% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 39.2% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 19.4% | 97/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 18.8% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.74× | 78/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.12× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.37× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 14.64× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 6.56 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 18.8% | 95/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.48× | 22/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 34.8% | 0/100 |
| Operating margin volatility | 5.1% | 63/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 14.9% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | 28.2% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
KRW millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,568,007 | 3,001,295 | 2,938,756 | 3,497,146 | 4,556,972 |
| Cost of revenue | 841,556 | 1,532,847 | 1,448,652 | 1,785,961 | 2,040,331 |
| Gross profit | 726,451 | 1,468,448 | 1,490,104 | 1,711,185 | 2,516,640 |
| Selling, general & admin | 189,142 | 484,821 | 284,558 | 389,818 | 447,419 |
| Operating income | 537,309 | 983,627 | 1,205,546 | 1,321,366 | 2,069,221 |
| Interest expense | 29,141 | 273,268 | 147,788 | 145,724 | 141,368 |
| Pre-tax income | 561,283 | 1,009,025 | 1,231,334 | 1,384,869 | 2,118,631 |
| Income tax | 167,693 | 210,968 | 282,272 | 344,567 | 504,301 |
| Net income | 393,589 | 798,056 | 857,691 | 1,083,316 | 1,784,352 |
| Diluted EPS | KRW5,949.00 | KRW11,432.00 | KRW13,334.00 | KRW14,616.00 | KRW24,091.00 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
6.56 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: DART (opendart.fss.or.kr). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 1, 2025 · Data updated May 15, 2026